WebAug 1, 2024 · Corium has a robust development pipeline focused on addressing unmet needs in the treatment of patients with CNS conditions. In November 2024 , all of Corium's outstanding stock was acquired by an ... WebSep 19, 2024 · BOSTON, Sept. 19, 2024 /PRNewswire/ -- Corium, Inc., a fully-integrated biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies,...

Corium Secures $235 Million in Debt Financing Markets Insider

WebOct 20, 2024 · Corium and Gurnet Point Capital Announce Manufacturing Business Acquisition and a $100 Million Neuroscience Therapeutics Investment by Webster Equity … WebSep 29, 2024 · BOSTON, Sept. 29, 2024 /PRNewswire/ -- Corium, Inc., a fully-integrated biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies,... thinking about thinking is known as

Corium Launches ADLARITY® (donepezil transdermal system) for …

WebMar 16, 2024 · CELEBRATION, Fla., March 16, 2024 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (the Company, or KemPharm), a specialty pharmaceutical … WebOct 16, 2024 · After receiving FDA approval in March 2024, Corium, a biopharmaceutical company, recently announced the commercial availability of its once-weekly donepezil transdermal system (Adlarity) to treat patients with mild, moderate, or severe Alzheimer disease (AD) dementia. 1,2 WebMar 16, 2024 · In July 2024, Corium launched serdexmethylphenidate and dexmethylphenidate (Azstarys) for the treatment of attention-deficit/hyperactivity disorder in individuals aged 6 years and older, following the FDA approval in March 2024. Reference thinking about thinking term